Patent 9074019 was granted and assigned to Henry Ford Health System on July, 2015 by the United States Patent and Trademark Office.
Methods, systems and compositions comprising novel peptidomimetics are disclosed that can be used to inhibit calpain and, more specifically, to treat tissue damage caused by pathologic activation of calpains.